343 related articles for article (PubMed ID: 17889537)
1. Effect of varying the 4''-position of arbekacin derivatives on antibacterial activity against MRSA and Pseudomonas aeruginosa.
Hiraiwa Y; Minowa N; Usui T; Akiyama Y; Maebashi K; Ikeda D
Bioorg Med Chem Lett; 2007 Nov; 17(22):6369-72. PubMed ID: 17889537
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antibacterial activity of 5-deoxy-5-episubstituted arbekacin derivatives.
Hiraiwa Y; Usui T; Akiyama Y; Maebashi K; Minowa N; Ikeda D
Bioorg Med Chem Lett; 2007 Jul; 17(13):3540-3. PubMed ID: 17502146
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antibacterial activity of 4″ or 6″-alkanoylamino derivatives of arbekacin.
Sasaki K; Kobayashi Y; Kurihara T; Yamashita Y; Takahashi Y; Miyake T; Akamatsu Y
J Antibiot (Tokyo); 2015 Dec; 68(12):741-7. PubMed ID: 25990952
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 2''-amino-2''-deoxyarbekacin and its analogs having potent activity against methicillin-resistant Staphylococcus aureus.
Kondo S; Ikeda Y; Ikeda D; Takeuchi T; Usui T; Ishii M; Kudo T; Gomi S; Shibahara S
J Antibiot (Tokyo); 1994 Jul; 47(7):821-32. PubMed ID: 8071128
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus.
Watanabe T; Ohashi K; Matsui K; Kubota T
J Antimicrob Chemother; 1997 Apr; 39(4):471-6. PubMed ID: 9145819
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of arbekacin, alone and in combination, against methicillin-resistant Staphylococcus aureus.
Kono K; Takeda S; Tatara I; Arakawa K
Jpn J Antibiot; 1994 Jun; 47(6):710-9. PubMed ID: 8072179
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus.
Inoue M; Nonoyama M; Okamoto R; Ida T
Drugs Exp Clin Res; 1994; 20(6):233-9. PubMed ID: 7758395
[TBL] [Abstract][Full Text] [Related]
8. [Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus].
Kondo S
Jpn J Antibiot; 1994 Jun; 47(6):561-74. PubMed ID: 8072163
[TBL] [Abstract][Full Text] [Related]
9. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.
Sader HS; Rhomberg PR; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2015; 59(6):3263-70. PubMed ID: 25801559
[TBL] [Abstract][Full Text] [Related]
10. [Combined effects of arbekacin with other antibiotics against methicillin-resistant Staphylococcus aureus. II. The combined effect of arbekacin with imipenem or cefminox].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
Jpn J Antibiot; 1992 Aug; 45(8):958-64. PubMed ID: 1433902
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections.
Kono K; Takeda S; Tatara I; Arakawa K; Tanaka H; Miyake S; Minamikawa H; Hoshino H; Sato M; Hattori F
Jpn J Antibiot; 1994 Jun; 47(6):798-803. PubMed ID: 8072189
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro].
Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K
Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148
[TBL] [Abstract][Full Text] [Related]
13. New 2''-amino derivatives of arbekacin, potent aminoglycoside antibiotics against methicillin-resistant Staphylococcus aureus.
Kondo S; Shibahara S; Usui T; Kudo T; Tamura A; Gomi S; Ikeda Y; Ikeda D; Takeuchi T
J Antibiot (Tokyo); 1993 Mar; 46(3):531-4. PubMed ID: 8478274
[No Abstract] [Full Text] [Related]
14. In vitro and in vivo antimicrobial activity of TS2037, a novel aminoglycoside antibiotic.
Hirai Y; Maebashi K; Fushimi H; Hiraiwa Y; Murakami S; Usui T; Akiyama Y; Minowa N; Ikeda D
J Antibiot (Tokyo); 2018 Mar; 71(3):363-371. PubMed ID: 29348522
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of bactericidal activity of arbekacin in mixed culture with MRSA and Pseudomonas aeruginosa using an in vitro pharmacokinetic simulation system].
Tsuji A; Sugano T; Yamaguchi K; Goto S; Takada T; Takase Y; Yoshida T
Jpn J Antibiot; 1994 Jun; 47(6):655-63. PubMed ID: 8072174
[TBL] [Abstract][Full Text] [Related]
16. A newly recognized acetylated metabolite of arbekacin in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus.
Fujimura S; Tokue Y; Takahashi H; Nukiwa T; Hisamichi K; Mikami T; Watanabe A
J Antimicrob Chemother; 1998 Apr; 41(4):495-7. PubMed ID: 9598784
[No Abstract] [Full Text] [Related]
17. Synthesis and antibacterial activity of 1-N-[(S)-ω-amino-2-hydroxyalkyl] derivatives of dibekacin, 5-deoxydibekacin, 3'-deoxykanamycin A and gentamicin B.
Umemura E; Sakamoto Y; Takahashi Y; Miyake T
J Antibiot (Tokyo); 2015 Jun; 68(6):421-3. PubMed ID: 25712399
[No Abstract] [Full Text] [Related]
18. [Combined effects of arbekacin with other antibiotics against methicillin-resistant Staphylococcus aureus. I. The combined effect of arbekacin with fosfomycin or clavulanic acid/ticarcillin].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
Jpn J Antibiot; 1992 Aug; 45(8):949-57. PubMed ID: 1433901
[TBL] [Abstract][Full Text] [Related]
19. [In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli].
Lee J; Kim CK; Roh KH; Lee H; Yum JH; Yong D; Lee K; Chong Y
Korean J Lab Med; 2007 Aug; 27(4):292-7. PubMed ID: 18094591
[TBL] [Abstract][Full Text] [Related]
20. [Combination effect of arbekacin and cefepime on mixed culture of MRSA and P. aeruginosa].
Araake M; Hara T; Miyata A; Tani M; Ogawa H
Jpn J Antibiot; 2001 Feb; 54(2):69-78. PubMed ID: 11338680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
